Citius Pharmaceuticals (CTXR) Total Liabilities (2011 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Total Liabilities came in at $63.5 million in Q1 2026, up 9.59% YoY from $57.9 million in Q1 2025, and up 35.23% on a QoQ basis from $46.9 million in Q4 2025.
Citius Pharmaceuticals (CTXR) Total Liabilities (2011 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 16 years of Total Liabilities data on file, last reported at $63.5 million in Q1 2026.
- Quarterly Total Liabilities rose 9.59% year-over-year to $63.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.5 million (up 9.59% YoY) and the FY2025 annual result came in at $53.4 million, up 25.52% from the prior year.
- Total Liabilities rose to $63.5 million in Q1 2026, from $46.9 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $63.5 million in Q1 2026 to a low of $9.6 million in Q1 2022.
- A 5-year average of $28.7 million and a median of $12.2 million in 2023 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities fell 17.65% — and 2025, when it surged 456.3%.
- Tracing CTXR's Total Liabilities over 5 years: stood at $10.7 million in 2022, then gained by 13.06% to $12.1 million in 2023, then surged by 329.2% to $51.8 million in 2024, then retreated by 9.39% to $46.9 million in 2025, then jumped by 35.23% to $63.5 million in 2026.
- The last three Total Liabilities figures came in at $63.5 million (Q1 2026), $46.9 million (Q4 2025), and $53.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 10.03 Bn |
| 10 | Citius Pharmaceuticals | 15.96 Mn | 15.96 Mn | 1.00 Mn | 66.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 63.46 Mn |
| Dec 31, 2025 | 46.92 Mn |
| Sep 30, 2025 | 53.41 Mn |
| Jun 30, 2025 | 60.12 Mn |
| Mar 31, 2025 | 57.91 Mn |
| Dec 31, 2024 | 51.78 Mn |
| Sep 30, 2024 | 42.55 Mn |
| Jun 30, 2024 | 10.81 Mn |
| Mar 31, 2024 | 10.74 Mn |
| Dec 31, 2023 | 12.07 Mn |
| Sep 30, 2023 | 12.18 Mn |
| Jun 30, 2023 | 12.10 Mn |
| Mar 31, 2023 | 12.43 Mn |
| Dec 31, 2022 | 10.67 Mn |
| Sep 30, 2022 | 10.57 Mn |
| Jun 30, 2022 | 9.98 Mn |
| Mar 31, 2022 | 9.59 Mn |
| Dec 31, 2021 | 12.96 Mn |
| Sep 30, 2021 | 9.65 Mn |
| Jun 30, 2021 | 9.31 Mn |